Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM)

This publication has 15 references indexed in Scilit:

• National cancer prevalence estimation in France
  International Journal of Cancer, 2000
• Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study
  International Journal of Radiation Oncology*Biology*Physics, 2000
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
  Journal of Clinical Oncology, 1997
• Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
  Journal of Clinical Oncology, 1997
• Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
  Annals of Oncology, 1996
• A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
  Annals of Oncology, 1996
• Chemotherapy prolongs survival in inoperable pancreatic carcinoma
  British Journal of Surgery, 1994
• Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas
  Investigational New Drugs, 1994
• Cancer of the pancreas: 50 years of surgery
  Cancer, 1987
• Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study group
  Cancer, 1981